ライフサイエンスコーパス: I2

1 I2(II) is 4.565(2) A from the hydroxyl group with an occ

2 I2(II) is located interstitially between two phenyl ring

3 ifference -0.13 kg/m3, 95% CI -0.26 to 0.00, I2 = 0%, p = 0.04) than neonates of insulin-treated moth

4 s 24%; odds ratio, 0.82 [95% CI, 0.68-1.00]; I2 = 3%), less hospitalization (14 trials [n = 3706]; 38

5 57/10,000 [95% CI -106/10,000 to -8/10,000], I2 0%).

6 7/10,000 [95% CI -169/10,000 to -26/10,000], I2 0%, NNT 103 [95% CI 59 to 385]).

7 31/10,000, [95% CI -56/10,000 to -5/10,000], I2 0%, NNT 326, [95% CI 177 to 2,014]) and admission to

8 /10,000, [95% CI -204/10,000 to -50/10,000], I2 0%, NNT 79 [95% CI 49 to 201]) but not for multiparou

9 27/10,000, [95% CI -29/10,000 to 84/10,000], I2 55%).

10 justed HR 1.20, 95% CI 1.12-1.28, p < 0.001, I2 87%).

11 justed HR 2.25, 95% CI 1.83-2.76, p < 0.001, I2 99%).

12 ce = 0.59 days, 95% CI 0.36-0.83, p < 0.001, I2 = 100%), were more likely to be readmitted to hospita

13 oled OR = 1.37, 95% CI 1.28-1.47, p < 0.001, I2 = 83%), and were more likely to attend the emergency

14 oled OR = 1.97, 95% CI 1.41-2.76, p < 0.001, I2 = 99%) compared to patients without SMI.

15 ents; RR, 1.97; 95% CI, 1.71-2.27; P < .001, I2 = 0%).

16 ess (OR, 2.27; 95% CI, 1.54-3.35) (P < .001, I2 = 24%).

17 ity (OR, 1.79; 95% CI, 1.39-2.31) (P < .001, I2 = 64%), poor sleep quality (OR, 1.53; 95% CI, 1.11-2.

18 tically heterogeneous (Q = 203.50, P < .001, I2 = 65.60).

19 ents; RR, 1.96; 95% CI, 1.67-2.31; P < .001, I2 = 74%).

20 atio [RR],1.79; 95% CI, 1.47-2.18; P < .001, I2 = 85%); when SMR was qualitatively graded, the incide

21 31; 95% CI: 0.12, 0.50; z = 3.25; P = 0.001; I2 = 0%).

22 irst patient-controlled analgesia; P < .001; I2 = 19%).

23 n a visual analog scale at 2 days; P = .003; I2 = 0%).

24 ligrams per kilogram per 48 hours; P = .004; I2 = 17%) and that acupuncture delayed opioid use (mean

25 nfidence interval [CI] 1.21-2.80, p = 0.005, I2 = 100%), had hospital stays that were increased by 0.

26 ity (OR, 1.53; 95% CI, 1.11-2.10) (P = .009, I2 = 74%), and excessive daytime sleepiness (OR, 2.27; 9

27 e as follows: aHR = 1.04 (95% CI 0.54-2.01), I2 = 0%, p = 0.910; aHR = 0.73 (95% CI 0.26-2.06), p = 0

28 g ORR (RR, 1.31; 95% CI, 1.05-1.64; P = .02; I2 = 0%) in 5 studies.

29 tality (risk ratio, 0.93; 95% CI, 0.84-1.03; I2 = 0%).

30 an OR of death of 3.71 (95% CI, 1.25-11.03; I2 = 0%).

31 lligrams per kilogram per 48 hours; P = .03; I2 = 86%) and in pain improvement (mean difference, -0.5

32 ence (SMD), -0.12; [95% CI, -0.20 to -0.03]; I2 = 0%; Edmonton Symptom Assessment Scale score mean di

33 aring studies, and -0.27% (-0.50% to -0.04%, I2 64.1%, n = 7, p = 0.010) in trials of diabetes educat

34 or HbA1c (WMD: 0.02%; 95% CI: -0.01%, 0.04%; I2 = 51.0%).

35 5.78%; OR, 1.85 [95% CI, 1.03-3.33]; P=0.04, I2=62%).

36 25; 95% CI: -0.00, 0.50; z = 1.93; P = 0.05; I2 = 58%) and strong evidence to support improving muscl

37 o -0.02 on the visual analog scale; P < .05; I2 = 62%).

38 n HOMA-IR (WMD: -0.23; 95% CI: -0.40, -0.06; I2 = 51.7%) and fasting insulin (WMD: -0.40 muIU/mL; 95%

39 not urinalysis (RR 0.91, 95% CI 0.78-w1.07; I2 = 20%).

40 .5%) or Asian (RR: 0.82; 95% CI: 0.62, 1.09; I2 = 59.1%) studies.

41 isk difference was -12% (95% CI: -22 to -1%, I2 : 69%, p=0.03) when pooling only RCT (792 patients).

42 ax = 640 nm), and an eta(1) species [(eta(1)-I2)BiI4](3-) (lambdamax = 750 nm).

43 Interestingly, [(eta(1)-I2)BiI5](4-) decayed to ground state products with a fir

44 ted with 1 equiv of iodide to yield [(eta(1)-I2)BiI5](4-).

45 1) overall, -0.37% (95% CI -0.64% to -0.10%, I2 60.0%, n = 7, p = 0.020) in multicomponent clinic-bas

46 95% CI, 1.19-1.50]; No. of studies [K] = 10, I2 = 7.9%) compared with usual care, with absolute incre

47 .46 (95% confidence interval [CI] 1.01-2.11; I2 = 76%) for sexual health outcomes at <=6 months and O

48 cipants; pooled OR: 2.63; 95% CI: 1.35-5.11; I2: 67%; p-value = 0.01), dysuria (3,686 FGM/C and 3,482

49 ts (12 trials; RR, 1.63 [95% CI, 1.26-2.11]; I2 = 43%; ARD, 1.95% [95% CI, 0.48%-3.43%]); most advers

50 <200 cells/uL [cOR = 0.36, 95% CI: .04-3.13; I2 = 81.3%, P = .021]) and significant evidence among wo

51 e in age was -0.24 cm (95% CI: -0.34, -0.14; I2 = 30%), reflecting a compositional change (lower dens

52 otic prescribing (RR 0.97, 95% CI 0.82-1.15, I2 = 70%), but increased prescribing of antivirals (RR 2

53 09; 95% confidence interval [CI], 0.06-0.15; I2 = 0.60, P < .01; 15 trials).

54 oled RR of T2D was 1.07 (95% CI: 0.99, 1.15; I2 = 69.8%).

55 mong European (RR: 0.99; 95% CI: 0.85, 1.15; I2 = 73.5%) or Asian (RR: 0.82; 95% CI: 0.62, 1.09; I2 =

56 16; 95% CI: -0.08, 0.41; z = 1.34; P = 0.18; I2 = 67%) or any other outcome was found.

57 mug/m3 PM2.5 increase (95% CI: 1.023, 1.189; I2 = 0.00%).

58 atio [OR], 1.64 [95% CI, 0.78-3.44]; P=0.19, I2=84%), cardiac mortality (1.25% versus 0.72%; OR, 1.78

59 macrosomia risk (OR 0.32, 95% CI 0.08-1.19, I2 = 0%, p = 0.09) versus glyburide-exposed neonates.

60 risk reduction, 0.71% [95% CI, 0.19%-1.2%]; I2 = 36.1%).

61 bitals as an eta(2) ligated I2(*-), [(eta(2)-I2)BiI4](3-) (lambdamax = 640 nm), and an eta(1) species

62 The [(eta(2)-I2)BiI4](3-) subsequently reacted with 1 equiv of iodide

63 47; 95% confidence interval [CI]: 1.45-4.21; I2: 79%; p-value < 0.01), perineal tears (4,898 FGM/C an

64 zard ratio [aHR] = 0.73 [95% CI 0.44, 1.21], I2 = 0%, p = 0.228), in the risk of stillbirth (artemisi

65 its (odds ratio [OR] 2.92, 95% CI 2.02-4.22; I2 = 63.7%, 95% CI 4.4%-86.2%), use of a sterile blade t

66 = 2204]; SMD, 0.07 [95% CI, -0.09 to 0.23]; I2 = 68%).

67 RR] from 3 studies = 0.66, 95% CI: .20-2.24; I2 = 78.7%, P = .009).

68 g ORR (RR, 1.17; 95% CI, 0.89-1.53; P = .26; I2 = 0%) in 9 studies.

69 -0.98, p < 0.001, 12 estimates, n = 852,268, I2 = 51.8%; early menarche: RR = 1.19, 95% CI 1.11-1.28,

70 ng US studies (RR: 1.18; 95% CI: 1.10, 1.27; I2 = 51.3%), but not among European (RR: 0.99; 95% CI: 0

71 cipants; pooled OR: 2.04; 95% CI: 1.27-3.28; I2: 90%; p-value < 0.01).

72 urning for care (RR 1.00 95% CI = 0.77-1.29, I2 = 7%), or antibiotic prescribing (RR 0.97, 95% CI 0.8

73 ula of this compound is thus (CH3NH3)PbI3-2x(I2)x where x approximately 0.007 at room temperature.

74 difference, -0.57 d; 95% CI, -2.44 to 1.30; I2 = 0%), ventilator-associated events (risk ratio, 0.97

75 cipants; pooled OR: 1.51; 95% CI: 0.99-2.30; I2: 96%; p-value = 0.05).

76 .61 [95% CI, 0.47-0.78]; 17 RCTs [n = 3094]; I2 = 39.0%).

77 ference was -0.46% (95% CI -0.60% to -0.31%, I2 87.8%, p < 0.001) overall, -0.37% (95% CI -0.64% to -

78 rculating Mg category was 1.18 (1.06, 1.31) (I2 = 22%, P-heterogeneity = 0.27).

79 0.72%; OR, 1.78 [95% CI, 0.58-5.46]; P=0.31, I2=18%), and myocardial infarction (1.28% versus 2.66%;

80 pioid consumption at 1 and 2 weeks (P = .32, I2 = 87%), and for preoperative exercise, the mean diffe

81 difference 0.78 kg/m2, 95% CI 0.23 to 1.33, I2 = 7%, p = 0.005) following metformin exposure than fo

82 difference, -0.16 d; 95% CI, -0.64 to 0.33; I2 = 0%), ICU length of stay (weighted mean difference,

83 radicalPD (-0.38 cm [95% CI: -0.44, -0.33]; I2 = 30%) was additionally driven by increasing breast a

84 igoanuric HUS (OR, 2.38 [95% CI, 1.30-4.35]; I2 = 2%), renal replacement therapy (OR, 1.90 [95% CI, 1

85 .70, 95% confidence interval [CI]: .36-1.36; I2 = 64.5%, P = .006; adjusted risk ratio [aRR] from 3 s

86 ildren were vaccinated: 22% (95% CI, 1%-38%; I2 = 0%; N = 1903) against acute respiratory infections

87 robiotics (WMD: -1.84; 95% CI: -3.30, -0.38; I2 = 23.6%), but not synbiotics (WMD: -0.85; 95% CI: -2.

88 h adherence >=70%, 0.27 [95% CI, 0.19-0.39]; I2 = 0%) in 6 trials.

89 110/954 individuals; 95% CI, 10.2% to 23.4%, I2 = 70.1%).

90 issed (95% confidence interval: 15.3%-35.4%; I2 = 0%).

91 forearm (WMD: 0.53%; 95% CI: -0.35%, 1.42%; I2 = 55%; 95% CI: 0%, 85%; n = 415 from 4 trials).

92 ct on admissions (RR 0.93, 95% CI 0.61-1.42, I2 = 34%), returning for care (RR 1.00 95% CI = 0.77-1.2

93 .55, p < 0.001, 23 estimates, n = 1,185,444, I2 = 87.8%).

94 come countries (cOR = 0.24, 95% CI: .13-.45; I2 = 0.0%, P = .77) but not in low and middle-income cou

95 synbiotics (WMD: -0.85; 95% CI: -2.17, 0.47; I2 = 96.6%), were associated with a significant reductio

96 hood RR, 0.58 [95% CI, 0.22-1.53]; n = 4738; I2 = 66.3%; absolute risk reduction range, -3.1% to -13.

97 difference was 0.61 (95% CI, -0.27 to 1.49; I2 = 75%).

98 OR]: 1.41, 95% CI 1.20-1.66, p = 2.7 x 10-5, I2 = 0%, 95% CI 0-29).

99 -0.93, p < 0.001, 11 estimates, n = 833,529, I2 = 85.4%) and higher for early versus later menarche (

100 sed interventions, -0.87% (-1.20% to -0.53%, I2 91.0%, n = 13, p < 0.001) in pharmacist task-sharing

101 cipants; pooled OR: 2.11; 95% CI: 0.80-5.54; I2: 90%; p-value = 0.10), instrumental delivery (5,176 F

102 80 [95% CI, 0.73-0.87]; 9 RCTs [n = 12 551]; I2 = 0%).

103 educe STI risk (OR, 1.31 [95% CI, 1.10-1.56; I2 = 40%, n = 5253).

104 ), and death (OR, 5.13 [95% CI, 1.50-17.57]; I2 = 55%).

105 -1.28, p < 0.001, 21 estimates, n = 890,583, I2 = 68.1%).

106 ar spine (WMD: 0.74%; 95% CI: -0.10%, 1.59%; I2 = 47%; 95% CI: 0%, 81%; n = 527 from 5 trials) or the

107 ng of antivirals (RR 2.65, 95% CI 1.95-3.60; I2 = 0%).

108 = 1334]; SMD, 0.18 [95% CI, -0.24 to 0.61]; I2 = 87%; Functional Assessment of Chronic Illness Thera

109 = 2,075; SMD = -0.87, 95% CI -1.11 to -0.63; I2 = 82.7%, p = 0.000) and anxiety (k = 15; n = 1,395; S

110 smission rates were 3.01 (95% CI, 1.19-7.64; I2 = 97%) and 1.60 (95% CI, 0.86-2.98; I2 = 89%), respec

111 tion (4 trials; RR, 1.47; 95% CI, 1.30-1.66; I2 = 42%; absolute risk difference, 24%; 95% CI, 12%-37%

112 elative risk [RR], 0.46 [95% CI, 0.33-0.66]; I2 = 67%; absolute risk reduction [ARD], -2.0% [95% CI,

113 rates (risk ratio, 0.58; 95% CI, 0.51-0.67; I2 = 0%), but there were no significant differences betw

114 risk reduction, 0.39% [95% CI, 0.09%-0.68%]; I2 = 0.0%) and cognitive decline (8 trials) (20.2% vs 21

115 43/21002 individuals; 95% CI, 9.0% to 13.7%, I2 = 95.8%).

116 difference -107.7 g, 95% CI -182.3 to -32.7, I2 = 83%, p = 0.005) and lower ponderal indices (mean di

117 2.66%; OR, 0.79 [95% CI, 0.22-2.79]; P=0.71, I2=65%) was similar with deferral versus performance of

118 0.55 (95% confidence interval [CI], .37-.71; I2 = 95.5%) and 0.76 (95% CI, .62-.86; I2 = 94.1%), resp

119 infarction (RR, 0.64 [95% CI, 0.57 to 0.71]; I2 = 0%; ARD, -0.81% [95% CI, -1.19 to -0.43%]), and com

120 60% (95% confidence interval [CI], 41%-72%; I2 = 0%; N = 2326) against laboratory-confirmed influenz

121 e to FOLFOXIRI-Bev was 69% (95% CI, 65%-72%; I2 = 25%).

122 peanut allergy (RR, 0.29; 95% CI, 0.11-0.74; I2 = 66%; P = .009).

123 o 0.25) on the visual analog scale (P = .74; I2 = 52%) and 6.58 (95% CI, -6.33 to 19.49) opioid consu

124 cipants; pooled OR: 1.43; 95% CI: 1.17-1.75; I2: 0%; p-value = 0.01), episiotomy (29,341 FGM/C and 39

125 ts (12 trials; RR, 1.43 [95% CI, 1.18-1.75]; I2 = 0%; ARD, 0.56% [95% CI, 0.09%-1.04%]) and gastroint

126 Universities Arthritis Index Scale (P = .78, I2 = 65%).

127 r outcomes (RR, 0.70 [95% CI, 0.63 to 0.78]; I2 = 36%; ARD, -1.39% [95% CI, -1.79 to -0.99%]).

128 cipants; pooled OR: 1.18; 95% CI: 0.78-1.79; I2: 63%; p-value = 0.40), or cesarean delivery (34,693 F

129 r (199.2-202.1), iodine value (104.8-125.7kg I2/kg) and cetane number (43.8-48.8), confirmed that the

130 without pNPWT was -12% (95%CI: -17% to -8%, I2: 54%, p&0.00001) in favor of pNPWT.

131 aTeq vaccine strain constellation of G1-P[8]-I2-R2-C2-M2-A3-N2-T6-E2-H3, with most of the gene segmen

132 ]; 24 effects [from 23 studies]; n = 12 801; I2 = 57.0%).

133 STI incidence (OR, 0.66 [95% CI, 0.54-0.81; I2 = 74%]).

134 at <=6 months and OR 1.51 (95% CI 1.27-1.81; I2 = 40%) for sexual health outcomes at >6-12 months.

135 cipants; pooled OR: 1.89; 95% CI: 1.26-2.82; I2: 96%; p-value < 0.01), and prolonged labor (7,516 FGM

136 ]), stroke (RR, 0.71 [95% CI, 0.62 to 0.82]; I2 = 0; ARD, -0.38% [95% CI, -0.53% to -0.23%]), myocard

137 up (mean difference 440 g, 95% CI 50 to 830, I2 = 4%, p = 0.03).

138 tes (odds ratio [OR] 0.67, 95% CI 0.53-0.84, I2 = 0%), with no heterogeneity (2 trials, 2,397 women).

139 hazard ratio [aHR] = 0.35, 95% CI: .15-.84; I2 = 0%, P = .64]).

140 cipants; pooled OR: 1.66; 95% CI: 0.97-2.84; I2: 86%; p-value = 0.06), urinary tract infection (4,493

141 by ultrasound (OR: 2.40; 95% CI: 1.50, 3.84; I2 = 22.4%).

142 -.71; I2 = 95.5%) and 0.76 (95% CI, .62-.86; I2 = 94.1%), respectively.

143 y (risk ratio [RR], 0.56; 95% CI, 0.36-0.87; I2 = 36%; P = .009).

144 mortality (RR, 0.69 [95% CI, 0.54 to 0.88]; I2 = 54%; ARD, -0.43% [95% CI, -0.75% to -0.11%]), strok

145 /122356 individuals; 95% CI, 24.7% to 29.9%, I2 = 98.9%).

146 ement therapy (OR, 1.90 [95% CI, 1.25-2.90]; I2 = 17%), and death (OR, 5.13 [95% CI, 1.50-17.57]; I2

147 lood counts (FBC) (RR 0.80, 95% CI 0.69-0.92 I2 = 0%), blood cultures (RR 0.82, 95% CI 0.68-0.99; I2

148 r total mortality, 0.87 (95% CI: 0.82, 0.92; I2 = 3.7%) for CVD mortality, and 0.89 (95% CI: 0.85, 0.

149 ome countries (cOR = 1.13, 95% CI: .67-1.92; I2 = 18.8%, P = .30).In 3 populations, ART users with HI

150 CVD mortality, and 0.89 (95% CI: 0.85, 0.93; I2 = 0%) for cancer mortality.

151 isk ratio [RR], 0.86 [95% CI, 0.80 to 0.93]; I2 = 0%; absolute risk difference [ARD], -0.40% [95% CI,

152 r total mortality, 0.89 (95% CI: 0.85, 0.94; I2 = 28.9%) for CVD mortality, and 0.91 (95% CI: 0.84, 0

153 (high vs low) were 0.87 (95% CI: 0.81, 0.94; I2 = 67.9%) for total mortality, 0.87 (95% CI: 0.82, 0.9

154 >=50 copies/mL: cOR = 0.55, 95% CI: .32-.94; I2 = 0.0%, P = .23).There was weak evidence of decreased

155 difference, +0.17 d; 95% CI, -0.62 to 0.95; I2 = 0%), hospital length of stay (weighted mean differe

156 compartments were 0.91 (95% CI: 0.87, 0.95; I2 = 64.1%) for total mortality, 0.89 (95% CI: 0.85, 0.9

157 hest radiography (RR 0.81, 95% CI 0.68-0.96; I2 = 32%), but not urinalysis (RR 0.91, 95% CI 0.78-w1.0

158 CVD mortality, and 0.91 (95% CI: 0.84, 0.98; I2 = 26.3%) for cancer mortality.

159 7.64; I2 = 97%) and 1.60 (95% CI, 0.86-2.98; I2 = 89%), respectively.

160 , blood cultures (RR 0.82, 95% CI 0.68-0.99; I2 = 0%) and chest radiography (RR 0.81, 95% CI 0.68-0.9

161 s 42%; odds ratio, 0.80 [95% CI, 0.65-0.99]; I2 = 41%), and modestly lower symptom burden (11 trials

162 Optimal classification threshold was an I2 score of 20 (95% confidence interval [CI]: 18, 23), l

163 nalyses showed heterogeneity (I2 = 90.6% and I2 = 93.4%, respectively).

164 ply from readily available benzoic acids and I2.

165 enhanced ClNO3 formation for higher Br2 and I2 emission flux.

166 The transition states from both I1 and I2 to the native state are plastic and change with mutat

167 Both of the intermediates, I1 and I2, showed a propensity to self-associate under stirring

168 e and proceeds via two intermediates, I1 and I2.

169 mprehensive understanding of the host-I2 and I2-I2 binding interactions at a molecular level.

170 igating the voltammetric response of ICl and I2 under these conditions).

171 an differences, 95% confidence intervals and I2 were obtained by random effects meta-analyses.

172 en studies was assessed by Cochran's (Q) and I2 statistics.

173 study-specific ORs using the Q statistic and I2 statistic.

174 CO2(-) ligand exchange to generate 1-TFA and I2 as a soluble byproduct.

175 sient species assigned as the diiodide anion I2(*-) directly ligated to Bi, [Bi(I2(*-))Ix](n).

176 Here we present Arctic atmospheric I2 and snowpack iodide (I(-)) measurements, which were c

177 ide anion I2(*-) directly ligated to Bi, [Bi(I2(*-))Ix](n).

178 e have retrieved 13 mutations affecting both I2 and the multimerization domains of IntI1.

179 d in vivo, including human chondrocytes (C28/I2), human hepatic epithelial cells (L-02) and human tub

180 showed a similar antagonistic effect in C28/I2, L-02 and HK-2 cells.

181 Fractions were added to C28/I2 chondrocytes, grown in micromasses, ions with or with

182 3I, CH3OH, BrCH2Cl, CH3CH2OH, CH3CN, CH3NO2, I2), and a propyne clathrate (CH3CCH@Me,H,SiMe2.2CHCl3),

183 Heterogeneity was seen across cohorts (I2 = 51.1%-73.1% for each fatty acid) but not explained

184 Under the same experimental conditions, I2(*-) in CH3CN rapidly disproportionates with a tremend

185 L(-) with CuI formed the unique, neutral Cu2 I2 (L(.) ) complex of a ligand-centered radical, whereas

186 WMD: -0.52 mg/dL; 95% CI: -1.43, 0.38 mg/dL; I2 = 53.4%) or HbA1c (WMD: 0.02%; 95% CI: -0.01%, 0.04%;

187 significant heterogeneity between estimates (I2 = 90.7%).

188 packing of I2 molecules with an exceptional I2 storage density of 3.08 g cm(-3) in MFM-300(Sc).

189 e to replicate in cells that did not express I2.

190 ed a cell line that constitutively expressed I2 and allowed construction of the VACV I2L deletion mut

191 ons could have initially coexisted following I2 acquisition, paving the way for a gradual evolution t

192 able heterogeneity of DMFT/dmft values (from I2 = 94% up to I2 = 99.9%; p < 0.05) in children of diff

193 mation of I2 molecules, suggesting a 2I(-)-->I2+2e(-) redox couple.

194 ption, binding domains and dynamics of guest I2 molecules within these hosts have been achieved using

195 imited due to the presence of heterogeneity (I2 = 82.65%, p < 0.001) and evidence of possible publica

196 41), with high between-sample heterogeneity (I2 = 98%).

197 Pa), although analyses showed heterogeneity (I2 = 90.6% and I2 = 93.4%, respectively).

198 ant between-study statistical heterogeneity (I2 = 99.5%; tau2 = 182.5; P < .001).

199 8.7%-45.5%), with substantial heterogeneity (I2 = 68%).

200 ross population groups due to heterogeneity (I2) was 16.5%.

201 d quality of care were highly heterogeneous (I2 = 93.4% to 98.8%).

202 ons with type 2 diabetes were heterogeneous (I2 = 77.2%; P = .002), indicating gene-specific associat

203 Significantly, at high I2 loading an unprecedented self-aggregation of I2 molec

204 Here, we report high I2 adsorption in a series of robust porous metal-organic

205 but heterogeneity between studies was high (I2 = 73.8%).

206 al a comprehensive understanding of the host-I2 and I2-I2 binding interactions at a molecular level.

207 In this study, the electrochemistry of I(-), I2, and ICl has been investigated by cyclic voltammetry

208 In summary, the I(-)/I2/I(+) processes in nonhaloaluminate ILs involve a comp

209 be strongly electrophilic, and thus the I(-)/I2/I(+) redox processes are sensitive to the presence of

210 ng rise to two resolved I(-)/I3(-) and I3(-)/I2 processes, as per previous reports.

211 h good to excellent yields using inexpensive I2 as a catalyst.

212 t-compete the well-established PP1-inhibitor I2 in vitro.

213 tration of the transiently generated iodine (I2 ) as I3 (-) , this approach precludes undesired I2 -m

214 o previous measurements of molecular iodine (I2) have been reported in the Arctic.

215 dobenzene diacetate (PIDA)/molecular iodine (I2), under mild reaction conditions.

216 IYIY-I2-BODIPY alone and in combination with PDT modulates th

217 e the immunological impacts mediated by IYIY-I2-BODIPY in pre- and post-PDT conditions.

218 osuppressive conventional chemotherapy, IYIY-I2-BODIPY can act as an immune-stimulatory chemotherapeu

219 ruct, IYIY-diiodo-boron-dipyrromethene (IYIY-I2-BODIPY) and its scrambled counterpart YIYI-I2-BODIPY

220 Adoptive transfer of immune cells from IYIY-I2-BODIPY-treated survivor mice that were photoirradiate

221 PDT effects (drug-light interval 1 h), IYIY-I2-BODIPY induced stronger responses.

222 Only IYIY-I2-BODIPY enhanced the IFN-gamma(+) and IL-17(+) T-lymph

223 Moreover, photoirradiated IYIY-I2-BODIPY treated mice had high levels of effector T-cel

224 dine molecular orbitals as an eta(2) ligated I2(*-), [(eta(2)-I2)BiI4](3-) (lambdamax = 640 nm), and

225 -0.40 muIU/mL; 95% CI: -0.73, -0.07 muIU/mL; I2 = 49.4%).

226 ssed in a specific coefficient in the model (I2, describing the angular change of the backscattering

227 ng hydroxyl group of the [ScO4(OH)2] moiety [I2(I)...H-O = 2.263(9) A] with an occupancy of 0.268.

228 ough a redox reaction with iodine molecules (I2 ), which formed vacancies accompanied by a localized

229 henyl rings of neighboring ligand molecules [I2(II)...phenyl ring = 3.378(9) and 4.228(5) A].

230 The neutral (I2) and positive (I(+)) oxidation states of iodine are k

231 A novel I2-promoted direct conversion of arylacetic acids into a

232 Modeling shows that observed I2 levels are able to significantly increase ozone deple

233 e was no significant heterogeneity observed (I2 = 4.8%, P = .40).

234 trate the viability of oxidative addition of I2 to Pd(II).

235 king does not occur prior to the addition of I2 to the reaction mixture.

236 loading an unprecedented self-aggregation of I2 molecules into triple-helical chains within the confi

237 nding benzamides using a catalytic amount of I2 and TBHP as the green oxidant via the C-H bond cleava

238 d acid catalysis by partial decomposition of I2 to HI and suggest a halogen bond activation instead.

239 at lengths consistent with the formation of I2 molecules, suggesting a 2I(-)-->I2+2e(-) redox couple

240 on, leading to a highly efficient packing of I2 molecules with an exceptional I2 storage density of 3

241 letely unperturbed upon inclusion/removal of I2.

242 The initial binding site of I2 in MFM-300(Sc), I2(I), is located near the bridging h

243 here was low heterogeneity for all outcomes (I2 < 40%) except LGA.

244 e; however, the effect of prostaglandin (PG) I2 on ILC2 function is unknown.

245 on in this convergent approach involves Ph3P-I2-mediated formation of amidine upon condensation of an

246 N-acylbenzotriazoles in the presence of Ph3P-I2 as a dehydrating agent.

247 c and cyclic guanidines mediated by the Ph3P/I2 system is described.

248 tor, GKT137831, a NOX1/4 inhibitor, and Phox-I2, a NOX2 inhibitor.

249 een-study heterogeneity for both end points (I2 > 90%).

250 hough statistical heterogeneity was present (I2 = 52%), and 1 trial found high-intensity statins asso

251 1) while sparing EP2, EP3, and prostaglandin I2 receptors (IPs); Kb values (in nanomoles) are given i

252 ts, indicating a role for both prostaglandin I2 and E2 Activation of ERKs and p38, but not JNKs, by C

253 the counteracting eicosanoids prostaglandin I2, E1, E2, and A2, while in HRGEC only more prostagland

254 but not anti-inflammatory EP2, prostaglandin I2, or EP3 receptors.

255 d A2, while in HRGEC only more prostaglandin I2 was detected.

256 hanced autocrine production of prostaglandin I2 (PGI2, also called prostacyclin) in Cav-1 KO EC, and

257 pharmacological agonism of the prostaglandin I2 (IP) receptor in pancreatic beta-cells and in glomeru

258 ggers the rapid production of prostaglandins I2 and E2 through cyclooxygenase (COX)-1 and regulates g

259 sessed (Cochran Q statistic) and quantified (I2 statistic).

260 f the primary photoproduct, diiodide radical I2(*)(-), indicates that I4(*)(-) was formed via a secon

261 MFM-300(Sc) exhibits fully reversible I2 uptake of 1.54 g g(-1), and its structure remains com

262 r reduction in coronary artery disease risk (I2 = 0% for heterogeneity in genetic associations; P = .

263 e initial binding site of I2 in MFM-300(Sc), I2(I), is located near the bridging hydroxyl group of th

264 nd medium or high flow velocities (mean [SD] I2, 0.3 [5.3], 20.4 [6.4], and 21.7 [4.0], respectively)

265 Using chemical ionization mass spectrometry, I2 was observed in the atmosphere at mole ratios of 0.3-

266 ll statistical heterogeneity across studies (I2, 3.5%).

267 small amount of heterogeneity among studies (I2 = 28.9%; Q = 18.27, P = .16), and the funnel plot pro

268 of heterogeneity was observed among studies (I2 = 60.1%).

269 was substantial heterogeneity among studies (I2 = 74%).

270 was significant heterogeneity among studies (I2 = 91.35%).

271 o [OR], 1.56; 95% CI, 1.25-1.94; 14 studies; I2, 39%) and low birth weight (OR, 1.96; 95% CI, 1.24-3.

272 est (OR, 2.50; 95% CI, 1.70-3.67; 5 studies; I2, 0%), studies not reporting such conflicts showed mor

273 o: -0.86 (95% CI, -1.44 to -0.29; 6 studies; I2 = 0%) for metformin and -0.50 to -0.94 for orlistat.

274 -4.0 mm Hg (95% CI, -5.6 to -2.5; 6 studies; I2 = 17%) for diastolic blood pressure.

275 -6.4 mm Hg (95% CI, -8.6 to -4.2; 6 studies; I2 = 51%) for systolic blood pressure and -4.0 mm Hg (95

276 ght (OR, 1.96; 95% CI, 1.24-3.10; 8 studies; I2, 48%), with a trend toward higher risks for exposure

277 lts (OR, 1.34; 95% CI, 1.08-1.66; 9 studies; I2, 30%).

278 We concluded that I2 is required for virion morphogenesis, release of the

279 racycline-inducible mutant demonstrated that I2-deficient virions are defective in cell entry.

280 ctic atmospheric composition, and imply that I2 is likely a dominant source of iodine atoms in the Ar

281 orescence microscopy experiments showed that I2 colocalized with a major membrane protein of immature

282 The I2 protein is conserved in all poxviruses that infect ve

283 The I2 score derived from these features provided a measure

284 The I2 score derived from these markers highlights the utili

285 The I2 state is more unfolded, but it retains some residual

286 S and study heterogeneity as measured by the I2 statistic.

287 recombination through the acquisition of the I2 alpha-helix.

288 ion or entry that is affected by loss of the I2 protein.

289 IgD1 reveals that it actually belongs to the I2 set of IgSF folds.

290 analyses, quantified heterogeneity using the I2 statistic, and explored it with subgroup analyses by

291 dels and heterogeneity was assessed with the I2 statistic.

292 For example, charge transfer from I(-) to I2 gives rise to the linear, symmetrical [I-I-I](-) anio

293 erall one electron per iodide ion process to I2 via an I3(-) intermediate, giving rise to two resolve

294 ity of DMFT/dmft values (from I2 = 94% up to I2 = 99.9%; p < 0.05) in children of different ages (5-7

295 s I3 (-) , this approach precludes undesired I2 -mediated decomposition which can otherwise limit syn

296 double decarboxylative activations that use I2 as the terminal oxidant.

297 a-analyses; heterogeneity was examined using I2 statistic.

298 Heterogeneity was explored using I2, stratified analysis, and meta-regression, and public

299 ), with significant between-study variation (I2 = 96.8%; P < .001).

300 P(III) /P(V) hexameric rings or reacted with I2 to give trimeric P(V) variants.

301 rms more crowded complexes in reactions with I2, PhCl, and Al2Me6, which generate (C5Me5)3ThI, (C5Me5

302 2-BODIPY) and its scrambled counterpart YIYI-I2-BODIPY have been prepared.